Overview

Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade

Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Should the dose of sugammadex in morbid obese patients be calculated on the real body weight or the ideal body weight? To study the pharmacodynamics of sugammadex in morbidly obese patients by comparing 1 mg/kg IBW versus 1 mg/kg TBW versus placebo.
Phase:
Phase 3
Details
Lead Sponsor:
St. Antonius Hospital